TY  - JOUR
AU  - Laza-Briviesca, Raquel
AU  - Cruz-Bermúdez, Alberto
AU  - Nadal, Ernest
AU  - Insa, Amelia
AU  - García-Campelo, María Del Rosario
AU  - Huidobro, Gerardo
AU  - Dómine, Manuel
AU  - Majem, Margarita
AU  - Rodríguez-Abreu, Delvys
AU  - Martínez-Martí, Alex
AU  - De Castro Carpeño, Javier
AU  - Cobo, Manuel
AU  - López Vivanco, Guillermo
AU  - Del Barco, Edel
AU  - Bernabé Caro, Reyes
AU  - Viñolas, Nuria
AU  - Barneto Aranda, Isidoro
AU  - Viteri, Santiago
AU  - Massuti, Bartomeu
AU  - Casarrubios, Marta
AU  - Sierra-Rodero, Belén
AU  - Tarín, Carlos
AU  - García-Grande, Aránzazu
AU  - Haymaker, Cara
AU  - Wistuba, Ignacio I
AU  - Romero, Atocha
AU  - Franco, Fernando
AU  - Provencio, Mariano
PY  - 2021
DO  - 10.1002/ctm2.491
UR  - https://hdl.handle.net/10668/25724
T2  - Clinical and translational medicine
AB  - Immunotherapy is being tested in early-stage non-small cell lung cancer (NSCLC), and achieving higher rates of complete pathological responses (CPR) as compared to standard of care. Early identification of CPR patients has vital clinical implications....
LA  - en
KW  - biomarkers
KW  - chemoimmunotherapy
KW  - immune cells
KW  - neoadjuvant
KW  - non-small cell lung cancer
KW  - Aged
KW  - Antigens, CD19
KW  - Antineoplastic Agents
KW  - Area Under Curve
KW  - B-Cell Maturation Antigen
KW  - Biomarkers, Tumor
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Female
KW  - Humans
KW  - Immunotherapy
KW  - Leukocytes, Mononuclear
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Neoadjuvant Therapy
KW  - Neoplasm Staging
KW  - Nerve Growth Factor
KW  - Neurotrophin 3
KW  - ROC Curve
KW  - Vascular Endothelial Growth Factor D
TI  - Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.
TY  - research article
VL  - 11
ER  -